Optimal Pharmaceuticals to Support Blood Pressure Management

Paul H. Pronovost, MD, FACP, FASN; Interim Chief, Section of Nephrology, Hypertension and Kidney Transplantation at the Lewis Katz School of Medicine at Temple University discusses challenges in the medical management of hypertension. Despite the knowledge that blood-pressure-reducing medications effectively reduce the risk of patients being diagnosed with cardiovascular and kidney disease, studies show wide variations in prescribing patterns and inadequate clinical results experienced by patients. With the Temple Comprehensive Hypertension Program, hypertension experts from various clinical backgrounds work as a team to employ a broad consideration of diagnostic and advanced therapeutic options for patients with resistant or uncontrolled hypertension.

Created by

Temple Health


Paul Pronovost, MD, FACP, FASN

Paul Pronovost, MD, FACP, FASN

Chief, Nephrology
Associate Professor, Clinical Medicine, Lewis Katz School of Medicine at Temple University

Clinical Interests Home dialysis Peritoneal dialysis Hypertension Chronic kidney disease Onco-nephrology Glomerulonephritis Acute kidney injury Education MD, University of Connecticut School of Medicine, Farmington, ...

View full profile